AMTI

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Retrieved on: 
Wednesday, December 27, 2023

The combined company will now operate under the name “Cyclo Therapeutics, Inc.” and will continue trading on The Nasdaq Capital Market under the ticker symbol “CYTH”.

Key Points: 
  • The combined company will now operate under the name “Cyclo Therapeutics, Inc.” and will continue trading on The Nasdaq Capital Market under the ticker symbol “CYTH”.
  • Cyclo Therapeutics’ primary focus will continue to be on advancing its pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1).
  • “The completion of this merger with Applied Molecular Transport represents a significant milestone and bolsters our confidence and excitement for the future of Cyclo Therapeutics.
  • With the merger now closed and following our recent positive Type C meeting with the FDA, fundamentally the Company has never been stronger,” commented N. Scott Fine, CEO of Cyclo Therapeutics.

Applied Molecular Transport Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Cash and Cash Equivalents of $18.1 million, as of September 30, 2023
    SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023.
  • Total R&D expenses for the third quarter of 2023 were $0.3 million, compared to $18.2 million for the same period in 2022.
  • Total G&A expenses for the third quarter of 2023 were $7.0 million, compared to $7.3 million for the same period in 2022.
  • Net loss for the third quarter of 2023 was $6.9 million, compared to $25.2 million for the same period in 2022.

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

Retrieved on: 
Tuesday, November 28, 2023

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH).
  • Under the terms of the proposed transaction, shareholders of Applied Molecular will receive 0.174 shares of Cyclo for each share of Applied Molecular that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 15, 2023

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023.
  • “Our number one priority remains to be the solid operational execution of our TransportNPC™ study.
  • We remain hopeful that we will bring enrollment for this important study to a close in the coming months,” commented N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics.
  • “Further, during the quarter we entered into a strategic merger agreement with Applied Molecular Transport, which we expect to close before year end.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SMMF, AMTI, SATS, AMNB

Retrieved on: 
Wednesday, October 18, 2023

Under the terms of the agreement, SMMF shareholders are expected to own 50% of the combined company.

Key Points: 
  • Under the terms of the agreement, SMMF shareholders are expected to own 50% of the combined company.
  • Under the terms of the agreement, AMTI shareholders are expected to receive 0.174 shares of Cyclo per share they own.
  • Under the terms of the agreement, SATS shareholders are expected to receive 2.85 shares of DISH per share they own.
  • Under the terms of the agreement, AMNB shareholders will receive 1.35 shares of Atlantic per share they own.

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

Retrieved on: 
Thursday, September 28, 2023

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH).
  • Under the terms of the proposed transaction, shareholders of Applied Molecular will receive 0.174 shares of Cyclo for each share of Applied Molecular that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Lifshitz Law PLLC Announces Investigations of EBC, AMTI, SPLK

Retrieved on: 
Sunday, September 24, 2023

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of EBC and Cambridge Bancorp.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of EBC and Cambridge Bancorp.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of AMTI to Cyclo Therapeutics, Inc. for 0.174 shares of Cyclo Therapeutics, Inc. per share of AMTI common stock owned.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SPLK to Cisco Systems, Inc. for $157.00 in cash per share of SPLK common stock owned.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

AMTI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Applied Molecular Transport Inc. Is Fair to Shareholders

Retrieved on: 
Thursday, September 21, 2023

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Molecular Transport Inc. (NASDAQ: AMTI) to Cyclo Therapeutics, Inc. for 0.174 shares of Cyclo for each share of Applied Molecular is fair to Applied Molecular shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Molecular Transport Inc. (NASDAQ: AMTI) to Cyclo Therapeutics, Inc. for 0.174 shares of Cyclo for each share of Applied Molecular is fair to Applied Molecular shareholders.
  • The investigation concerns whether Applied Molecular and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Applied Molecular shareholders; (2) determine whether Cyclo is underpaying for Applied Molecular; and (3) disclose all material information necessary for Applied Molecular shareholders to adequately assess and value the merger consideration.
  • On behalf of Applied Molecular shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Retrieved on: 
Thursday, September 21, 2023

Following the closing of the Merger, the combined company will operate under the name “Cyclo Therapeutics, Inc.” and will continue trading on The Nasdaq Capital Market under the ticker symbol “CYTH”.

Key Points: 
  • Following the closing of the Merger, the combined company will operate under the name “Cyclo Therapeutics, Inc.” and will continue trading on The Nasdaq Capital Market under the ticker symbol “CYTH”.
  • The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1).
  • “We are extremely pleased to enter into this merger agreement with Applied Molecular Transport,” commented N. Scott Fine, CEO of Cyclo Therapeutics.
  • Cyclo Therapeutics has continued to demonstrate its commitment to developing life-changing medicines and execution across clinical and regulatory fronts.

Applied Molecular Transport Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Cash and Cash Equivalents of $22.5 million, as of June 30, 2023
    SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023.
  • Financial Results for the Second Quarter Ended June 30, 2023
    Research and development (R&D) expenses.
  • Total R&D expenses for the second quarter of 2023 were $2.6 million, compared to $22.8 million for the same period in 2022.
  • Total G&A expenses for the second quarter of 2023 were $7.0 million, compared to $9.4 million for the same period in 2022.